1
|
García-Gamboa R, Perfecto-Avalos Y, Gonzalez-Garcia J, Alvarez-Calderon MJ, Gutierrez-Vilchis A, Garcia-Gonzalez A. In vitro analysis of postbiotic antimicrobial activity against Candida Species in a minimal synthetic model simulating the gut mycobiota in obesity. Sci Rep 2024; 14:16760. [PMID: 39033245 PMCID: PMC11271299 DOI: 10.1038/s41598-024-66806-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2024] [Accepted: 07/04/2024] [Indexed: 07/23/2024] Open
Abstract
Gut fungal imbalances, particularly increased Candida spp., are linked to obesity. This study explored the potential of Lactiplantibacillus plantarum cell-free extracts (postbiotics) to modulate the growth of Candida albicans and Candida kefyr, key members of the gut mycobiota. A minimal synthetic gut model was employed to evaluate the effects of Lactiplantibacillus plantarum postbiotics on fungal growth in mono- and mixed cultures. Microreactors were employed for culturing, fungal growth was quantified using CFU counting, and regression analysis was used to evaluate the effects of postbiotics on fungal growth. Postbiotics at a concentration of 12.5% significantly reduced the growth of both Candida species. At 24 h, both C. albicans and C. kefyr in monocultures exhibited a decrease in growth of 0.11 log CFU/mL. In contrast, mixed cultures showed a more pronounced antifungal effect, with C. albicans and C. kefyr reductions of 0.62 log CFU/mL and 0.64 log CFU/mL, respectively. Regression analysis using the Gompertz model supported the antifungal activity of postbiotics and revealed species-specific differences in growth parameters. These findings suggest that L. plantarum postbiotics have the potential to modulate the gut mycobiota by reducing Candida growth, potentially offering a therapeutic approach for combating fungal overgrowth associated with obesity.
Collapse
Affiliation(s)
- Ricardo García-Gamboa
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Av. General Ramon Corona 2514, 45138, Nuevo Mexico, Zapopan, Jalisco, Mexico.
| | - Yocanxóchitl Perfecto-Avalos
- Escuela de Ingenieria y Ciencias, Tecnologico de Monterrey, Av. General Ramon Corona 2514, 45138, Nuevo Mexico, Zapopan, Jalisco, Mexico
| | - Julieta Gonzalez-Garcia
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Av. General Ramon Corona 2514, 45138, Nuevo Mexico, Zapopan, Jalisco, Mexico
| | - María J Alvarez-Calderon
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Av. General Ramon Corona 2514, 45138, Nuevo Mexico, Zapopan, Jalisco, Mexico
| | - Abel Gutierrez-Vilchis
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Av. General Ramon Corona 2514, 45138, Nuevo Mexico, Zapopan, Jalisco, Mexico
| | - Alejandro Garcia-Gonzalez
- Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Av. General Ramon Corona 2514, 45138, Nuevo Mexico, Zapopan, Jalisco, Mexico.
| |
Collapse
|
2
|
Nouraei H, Zare S, Nemati M, Amirzadeh N, Motamedi M, Shabanzadeh S, Zomorodian K, Pakshir K. Comparative analysis of enzymatic profiles and biofilm formation in clinical and environmental Candida kefyr isolates. ENVIRONMENTAL MICROBIOLOGY REPORTS 2024; 16:e13282. [PMID: 38923398 PMCID: PMC11194042 DOI: 10.1111/1758-2229.13282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2024] [Accepted: 04/30/2024] [Indexed: 06/28/2024]
Abstract
The global landscape of Candida infections has seen a significant shift. Previously, Candida albicans was the predominant species. However, there has been an emergence of non-albicans Candida species, which are often less susceptible to antifungal treatment. Candida kefyr, in particular, has been increasingly associated with infections. This study aimed to investigate the profiles of enzymatic activity and biofilm formation in both clinical and non-clinical isolates of C. kefyr. A total of 66 C. kefyr isolates were analysed. The activities of proteinase and phospholipase were assessed using bovine serum albumin and egg yolk agar, respectively. Haemolysin, caseinolytic and esterase activities were evaluated using specific methods. Biofilm formation was investigated using crystal violet staining. The findings indicated that biofilm and proteinase activity were detected in 81.8% and 93.9% of all the isolates, respectively. Haemolysin activity was observed with the highest occurrence (95.5%) among normal microbiota isolates. Esterase activity was predominantly identified in dairy samples and was absent in hospital samples. Caseinase production was found with the highest occurrence (18.2%) in normal microbiota and hospital samples. Phospholipase activity was limited, found in only 3% of all the isolates. These findings reveal variations in enzyme activity between clinical and non-clinical C. kefyr isolates. This sheds light on their pathogenic potential and has implications for therapeutic strategies.
Collapse
Affiliation(s)
- Hasti Nouraei
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
| | - Samira Zare
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
| | - Maryam Nemati
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
| | - Neda Amirzadeh
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
| | - Marjan Motamedi
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
| | - Shafigheh Shabanzadeh
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
| | - Kamiar Zomorodian
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
- Basic Sciences in Infectious Diseases Research Center, School of MedicineShiraz University of Medical SciencesShirazIran
| | - Keyvan Pakshir
- Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
- Basic Sciences in Infectious Diseases Research Center, School of MedicineShiraz University of Medical SciencesShirazIran
| |
Collapse
|
3
|
Tóth Z, Bozó A, Kovács R, Balogh B, Balázs B, Forgács L, Kelentey B, Majoros L. The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms. Mycopathologia 2022; 188:111-118. [PMID: 36399230 PMCID: PMC10169879 DOI: 10.1007/s11046-022-00688-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 10/31/2022] [Indexed: 11/19/2022]
Abstract
AbstractUntil recently, little was known about the susceptibility pattern of Cyberlindnera fabianii (Cy. fabianii) planktonic cells and biofilms regarding the most frequently administered systemic antifungals, despite the high mortality rate and its potential role in catheter-related infections. In the current study, the activity of fluconazole, amphotericin B and echinocandins (anidulafungin, caspofungin and micafungin) was determined against planktonic and sessile cells of Cy. fabianii clinical isolates (n = 8). Planktonic minimum inhibitory concentrations (MICs) ranged from 1 to 2, from 0.25 to 1, from 0.015 to 0.06, from 0.03 to 0.12 and from 0.25 to 0.5 mg/l for fluconazole, amphotericin B, anidulafungin, caspofungin and micafungin, respectively. One-day-old biofilms were highly resistant to fluconazole (MIC ranged from 512 to > 512) compared to planktonic counterparts, but not to amphotericin B (MIC ranged from 0.25 to 2 mg/l) and echinocandins (MIC ranged from 0.06 to 2 mg/l). Based on the calculated planktonic killing rates, the highest activity was observed in the case of anidulafungin (k values ranged from 0.37 to 2.09), while micafungin, caspofungin, amphotericin B and fluconazole exerted 0.46–1.47, 0.14–0.86, −0.03 to 2.08 and −0.15 to 0.09 killing rate value ranges, respectively. The obtained in vitro planktonic and sessile susceptibility patterns suggest that echinocandins and amphotericin B may be the most reliable treatment option for the treatment of Cy. fabianii infections.
Collapse
|
4
|
Overview on the Infections Related to Rare Candida species. Pathogens 2022; 11:pathogens11090963. [PMID: 36145394 PMCID: PMC9505029 DOI: 10.3390/pathogens11090963] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 08/19/2022] [Accepted: 08/21/2022] [Indexed: 11/30/2022] Open
Abstract
Atypical Candida spp. infections are rising, mostly due to the increasing numbers of immunocompromised patients. The most common Candida spp. is still Candida albicans; however, in the last decades, there has been an increase in non-Candida albicans Candida species infections (e.g., Candida glabrata, Candida parapsilosis, and Candida tropicalis). Furthermore, in the last 10 years, the reports on uncommon yeasts, such as Candida lusitaniae, Candida intermedia, or Candida norvegensis, have also worryingly increased. This review summarizes the information, mostly related to the last decade, regarding the infections, diagnosis, treatment, and resistance of these uncommon Candida species. In general, there has been an increase in the number of articles associated with the incidence of these species. Additionally, in several cases, there was a suggestive antifungal resistance, particularly with azoles, which is troublesome for therapeutic success.
Collapse
|
5
|
Spiliopoulou A, Kolonitsiou F, Vrioni G, Tsoupra S, Lekkou A, Paliogianni F. Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature. J Mycol Med 2021; 32:101236. [PMID: 34974339 PMCID: PMC8694783 DOI: 10.1016/j.mycmed.2021.101236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 12/19/2021] [Accepted: 12/20/2021] [Indexed: 11/29/2022]
Abstract
Candida kefyr (Kluyveromyces marxianus), an ascomycetous environmental yeast, occasionally isolated from dairy products, represents an uncommon but emerging pathogen in immunocompromised patients. Herein, we present a case of C. kefyr pyelonephritis in a 41-year-old, previously immunocompetent, patient who was hospitalized in an COVID-19 ICU. Pyelonephritis was associated with caliectasis and obstruction due to possible fungus ball formation. Predisposing factors included ICU stay, use of broad spectrum antibiotics and steroids, central venous catheterization, mechanical ventilation and urologic manipulation. Susceptibility testing revealed high MIC values to amphotericin B. Infection was effectively controlled by prolonged administration of fluconazole without further surgical intervention. COVID-19 complicated with invasive candidiasis is an increasingly observed clinical situation that warrants high suspicion index and careful evaluation of laboratory data.
Collapse
Affiliation(s)
| | | | - Georgia Vrioni
- Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Stamatia Tsoupra
- Department of Internal Medicine, University Hospital of Patras, Greece
| | - Alexandra Lekkou
- Department of Internal Medicine, Division of Infectious Diseases, University Hospital of Patras, Greece
| | - Fotini Paliogianni
- Department of Microbiology, University Hospital of Patras, Patras, Greece
| |
Collapse
|
6
|
Malchikova A, Klyasova G. In vitro activity of anidulafungin, caspofungin, fluconazole and amphotericin B against biofilms and planktonic forms of Candida species isolated from blood culture in patients with hematological malignancies. J Mycol Med 2021; 31:101162. [PMID: 34147758 DOI: 10.1016/j.mycmed.2021.101162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 04/20/2021] [Accepted: 05/31/2021] [Indexed: 10/21/2022]
Abstract
OBJECTIVE The aim of the present study was to evaluate the in vitro susceptibility of anidulafungin, caspofungin, fluconazole and conventional amphotericin B against biofilms and planktonic forms of Candida species isolated from blood culture in patients with hematological malignancies. MATERIALS AND METHODS Antifungal susceptibility for planktonic forms and biofilms of Candida was determined by broth microdilution method as described by Clinical and Laboratory Standards Institute M27 methodology and metabolic XTT-based [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] reduction assay, respectively. RESULTS A total of 75 Candida isolates were evaluated between 2006-2018 yy at the National Research Center for Hematology, Russia, Moscow. Biofilm production was detected in 34 (45.3%) Candida species. Antifungal susceptibility was tested for 27 common species of Candida forming biofilms (8 C.krusei, 7 C.tropicalis, 7 C.albicans, 5 C.parapsilosis). MICs below the susceptibility breakpoints were found for 100% of planktonic forms of Candida species for anidulafungin, 85.2% for caspofungin, and 66.7% for fluconazole. Amphotericin B MIC90 for Candida species were less than or equal to 1 μg/ml. Candida biofilms were susceptible in vitro for both tested echinocandins, but MIC80 of anidulafungin were lower compared to caspofungin. The highest MIC80 against Candida biofilms was found for fluconazole (>1,024 μg/ml for all tested isolates) and for conventional amphotericin B (range 4-16 μg/ml). CONCLUSION The majority of Candida isolates grown as planktonic forms were susceptible to anidulafungin, caspofungin, conventional amphotericin B and fluconazole. Anidulafungin displayed higher activity against Candida biofilms than caspofungin. All Candida biofilms were resistant to fluconazole and conventional amphotericin B.
Collapse
Affiliation(s)
- Anna Malchikova
- Laboratory of Clinical Microbiology, Mycology and Antibiotic Therapy, National Research Center for Hematology, Noviy Zykovskiy proezd 4A, Moscow, 125167, Russian Federation.
| | - Galina Klyasova
- Head of the Laboratory of Clinical Microbiology, Mycology and Antibiotic Therapy, National Research Center for Hematology Moscow, Russian Federation.
| |
Collapse
|
7
|
Aldejohann AM, Theuersbacher J, Haug L, Lamm OS, Walther G, Kurzai O, Hillenkamp J, Kampik D. First case of Kluyveromyces marxianus ( Candida kefyr) late onset keratitis after lamellar endothelial corneal graft. Med Mycol Case Rep 2021; 32:21-24. [PMID: 33665066 PMCID: PMC7902762 DOI: 10.1016/j.mmcr.2021.02.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 01/18/2021] [Accepted: 02/08/2021] [Indexed: 11/15/2022] Open
Abstract
We present a case of Kluyveromyces marxianus keratitis nine months after Descement's membrane endothelial keratoplasty (DMEK) in a patient with Fuchs endothelial disease. Endothelial scraping revealed this rare yeast infection at the interface between graft and host cornea. Immediate antifungal treatment with intracameral and corneal intrastromal injections of voriconazole and amphotericin B remained unsuccessful, requiring penetrating keratoplasty. This case highlights the challenging management of keratomycosis in patients with endothelial grafts.
Collapse
Affiliation(s)
- Alexander M Aldejohann
- Julius-Maximilians-University, Institute for Hygiene and Microbiology, Josef-Schneider- Str.2, 97080, Würzburg, Germany
| | - Johanna Theuersbacher
- University Hospital of Würzburg, Department of Ophthalmology, Josef- Schneider-Str. 11, 97080, Würzburg, Germany
| | - Lukas Haug
- Julius-Maximilians-University, Institute of Pathology, Josef-Schneider-Str. 2, 97080, Würzburg, Germany
| | - Olga S Lamm
- University Hospital of Würzburg, Department of Ophthalmology, Josef- Schneider-Str. 11, 97080, Würzburg, Germany
| | - Grit Walther
- National Reference Center for Invasive Fungal Infections NRZMyk, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (HKI), Adolf-Reichwein-Str. 23, 07745, Jena, Germany
| | - Oliver Kurzai
- Julius-Maximilians-University, Institute for Hygiene and Microbiology, Josef-Schneider- Str.2, 97080, Würzburg, Germany.,National Reference Center for Invasive Fungal Infections NRZMyk, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (HKI), Adolf-Reichwein-Str. 23, 07745, Jena, Germany
| | - Jost Hillenkamp
- University Hospital of Würzburg, Department of Ophthalmology, Josef- Schneider-Str. 11, 97080, Würzburg, Germany
| | - Daniel Kampik
- University Hospital of Würzburg, Department of Ophthalmology, Josef- Schneider-Str. 11, 97080, Würzburg, Germany
| |
Collapse
|
8
|
Synergistic Antifungal Activity of Chitosan with Fluconazole against Candida albicans, Candida tropicalis, and Fluconazole-Resistant Strains. Molecules 2020; 25:molecules25215114. [PMID: 33153228 PMCID: PMC7663520 DOI: 10.3390/molecules25215114] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 10/23/2020] [Accepted: 10/30/2020] [Indexed: 02/06/2023] Open
Abstract
(1) Background: Few antifungal drugs are currently available, and drug-resistant strains have rapidly emerged. Thus, the aim of this study is to evaluate the effectiveness of the antifungal activity from a combinational treatment of chitosan with a clinical antifungal drug on Candida albicans and Candida tropicalis. (2) Methods: Minimum inhibitory concentration (MIC) tests, checkerboard assays, and disc assays were employed to determine the inhibitory effect of chitosan with or without other antifungal drugs on C. albicans and C. tropicalis. (3) Results: Treatment with chitosan in combination with fluconazole showed a great synergistic fungicidal effect against C. albicans and C. tropicalis, but an indifferent effect on antifungal activity when challenged with chitosan-amphotericin B or chitosan-caspofungin simultaneously. Furthermore, the combination of chitosan and fluconazole was effective against drug-resistant strains. (4) Conclusions: These findings provide strong evidence that chitosan in combination with fluconazole is a promising therapy against two Candida species and its drug-resistant strains.
Collapse
|
9
|
Vitális E, Nagy F, Tóth Z, Forgács L, Bozó A, Kardos G, Majoros L, Kovács R. Candida
biofilm production is associated with higher mortality in patients with candidaemia. Mycoses 2020; 63:352-360. [DOI: 10.1111/myc.13049] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 01/04/2020] [Accepted: 01/08/2020] [Indexed: 12/17/2022]
Affiliation(s)
- Eszter Vitális
- Hospital Hygiene Ward Clinical Centre University of Debrecen Debrecen Hungary
| | - Fruzsina Nagy
- Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
- Doctoral School of Pharmaceutical Sciences University of Debrecen Debrecen Hungary
| | - Zoltán Tóth
- Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
- Doctoral School of Pharmaceutical Sciences University of Debrecen Debrecen Hungary
| | - Lajos Forgács
- Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
- Doctoral School of Pharmaceutical Sciences University of Debrecen Debrecen Hungary
| | - Aliz Bozó
- Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
| | - Gábor Kardos
- Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
| | - László Majoros
- Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
| | - Renátó Kovács
- Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
- Faculty of Pharmacy University of Debrecen Debrecen Hungary
| |
Collapse
|
10
|
Koutsoumanis K, Allende A, Alvarez‐Ordóñez A, Bolton D, Bover‐Cid S, Chemaly M, Davies R, De Cesare A, Hilbert F, Lindqvist R, Nauta M, Peixe L, Ru G, Simmons M, Skandamis P, Suffredini E, Cocconcelli PS, Fernández Escámez PS, Maradona MP, Querol A, Suarez JE, Sundh I, Vlak J, Barizzone F, Correia S, Herman L. Scientific Opinion on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA (2017-2019). EFSA J 2020; 18:e05966. [PMID: 32874212 PMCID: PMC7448045 DOI: 10.2903/j.efsa.2020.5966] [Citation(s) in RCA: 161] [Impact Index Per Article: 40.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The qualified presumption of safety (QPS) was developed to provide a safety pre-assessment within EFSA for microorganisms. Strains belonging to QPS taxonomic units (TUs) still require an assessment based on a specific data package, but QPS status facilitates fast track evaluation. QPS TUs are unambiguously defined biological agents assessed for the body of knowledge, their safety and their end use. Safety concerns are, where possible, to be confirmed at strain or product level, and reflected as 'qualifications'. Qualifications need to be evaluated at strain level by the respective EFSA units. The lowest QPS TU is the species level for bacteria, yeasts and protists/algae, and the family for viruses. The QPS concept is also applicable to genetically modified microorganisms used for production purposes if the recipient strain qualifies for the QPS status, and if the genetic modification does not indicate a concern. Based on the actual body of knowledge and/or an ambiguous taxonomic position, the following TUs were excluded from the QPS assessment: filamentous fungi, oomycetes, streptomycetes, Enterococcus faecium, Escherichia coli and bacteriophages. The list of QPS-recommended biological agents was reviewed and updated in the current opinion and therefore now becomes the valid list. For this update, reports on the safety of previously assessed microorganisms, including bacteria, yeasts and viruses (the latter only when used for plant protection purposes) were reviewed, following an Extensive Literature Search strategy. All TUs previously recommended for 2016 QPS list had their status reconfirmed as well as their qualifications. The TUs related to the new notifications received since the 2016 QPS opinion was periodically evaluated for QPS status in the Statements of the BIOHAZ Panel, and the QPS list was also periodically updated. In total, 14 new TUs received a QPS status between 2017 and 2019: three yeasts, eight bacteria and three algae/protists.
Collapse
|
11
|
Nagy F, Tóth Z, Bozó A, Czeglédi A, Rebenku I, Majoros L, Kovács R. Fluconazole is not inferior than caspofungin, micafungin or amphotericin B in the presence of 50% human serum against Candida albicans and Candida parapsilosis biofilms. Med Mycol 2019; 57:573-581. [PMID: 30339227 DOI: 10.1093/mmy/myy108] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 09/10/2018] [Accepted: 09/18/2018] [Indexed: 12/17/2023] Open
Abstract
Biofilm formation is a relevant risk factor for mortality in candidemia. Data about serum-based susceptibility testing against Candida biofilms are scant; therefore, the activity of fluconazole, amphotericin B, caspofungin and micafungin was determined against Candida albicans and C. parapsilosis biofilms with or without 50% human serum using XTT-based assays. Serum caused a remarkable adverse effect regarding biofilm structure for both species. Additionally, the ratio of nonviable cells increased for C. parapsilosis biofilms, as confirmed by fluorescent microscopy and flow cytometry. Despite impaired biofilm development, traditionally biofilm-active antifungals, surprisingly, showed decreased activity against C. albicans biofilms in serum at concentrations ranging from 0.5 to 1 mg/l and from 0.015 to 1 mg/l for amphotericin B and echinocandins, respectively (P < .01-.05). However, C. parapsilosis showed higher susceptibility to these antifungals due to reduced biofilm mass and the fungicidal effect of serum at concentrations ranging from 0.015 to 1 mg/l and from 0.015 to 512 mg/l for amphotericin B and echinocandins, respectively (P < .01-.05). Fluconazole exerted better antifungal activity in serum than traditionally biofilm-active antifungals against both examined biofilms. For fluconazole, significant differences were observed in susceptibility between serum-treated and serum-free biofilms at concentrations ranging from 0.015 to 8 mg/l and from 0.03 to 512 mg/l for C. albicans and C. parapsilosis isolates, respectively (P < .01-.05). The high antifungal activity of fluconazole in 50% serum both against C. albicans and C. parapsilosis biofilms supports the utility of fluconazole prophylaxis to reduce the risk of catheter-associated fungal infections.
Collapse
Affiliation(s)
- Fruzsina Nagy
- Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98, Hungary
| | - Zoltán Tóth
- Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98, Hungary
| | - Aliz Bozó
- Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98, Hungary
| | - András Czeglédi
- Department Pharmacology, Faculty of Pharmacy, University of Debrecen, Hungary, 4032 Debrecen, Nagyerdei krt. 98, Hungary
| | - István Rebenku
- Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Hungary, 4032 Debrecen, Egyetem sq. 1., Hungary
| | - László Majoros
- Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98, Hungary
| | - Renátó Kovács
- Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98, Hungary
- Faculty of Pharmacy, University of Debrecen, Debrecen, 4032 Debrecen, Nagyerdei krt 98, Hungary
| |
Collapse
|
12
|
Koutsoumanis K, Allende A, Alvarez-Ordóñez A, Bolton D, Bover-Cid S, Chemaly M, Davies R, De Cesare A, Hilbert F, Lindqvist R, Nauta M, Peixe L, Ru G, Simmons M, Skandamis P, Suffredini E, Cocconcelli PS, Fernández Escámez PS, Maradona MP, Querol A, Suarez JE, Sundh I, Vlak J, Barizzone F, Correia S, Herman L. Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019. EFSA J 2019; 17:e05753. [PMID: 32626372 PMCID: PMC7009089 DOI: 10.2903/j.efsa.2019.5753] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic pre-evaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit (TU) are, where possible and reasonable in number, reflected by 'qualifications' which should be assessed at the strain level by the EFSA's Scientific Panels. During the current assessment, no new information was found that would change the previously recommended QPS TUs and their qualifications. The list of microorganisms notified to EFSA from applications for market authorisation was updated with 47 biological agents, received between October 2018 and March 2019. Of these, 19 already had QPS status, 20 were excluded from the QPS exercise by the previous QPS mandate (11 filamentous fungi) or from further evaluations within the current mandate (9 notifications of Escherichia coli). Sphingomonas elodea, Gluconobacter frateurii, Corynebacterium ammoniagenes, Corynebacterium casei, Burkholderia ubonensis, Phaeodactylum tricornutum, Microbacterium foliorum and Euglena gracilis were evaluated for the first time. Sphingomonas elodea cannot be assessed for a possible QPS recommendation because it is not a valid species. Corynebacterium ammoniagenes and Euglena gracilis can be recommended for the QPS list with the qualification 'for production purposes only'. The following TUs cannot be recommended for the QPS list: Burkholderia ubonensis, due to its potential and confirmed ability to generate biologically active compounds and limited of body of knowledge; Corynebacterium casei, Gluconobacter frateurii and Microbacterium foliorum, due to lack of body of knowledge; Phaeodactylum tricornutum, based on the lack of a safe history of use in the food chain and limited knowledge on its potential production of bioactive compounds with possible toxic effects.
Collapse
|